Neurodegenerative disorders, both sporadic and inherited, are associated commonly with aging. The wide variety of likely mechanisms of action in different neurodegenerative disorders suggests that common features of normal aging underlie the increased predisposition to suffer from neurodegenerative disorders. The age dependence of neurodegeneration is unexplained and is a fundamental problem in understanding these common pathologies. Understanding the interaction of aging with neurodegeneration requires the development of model systems in which the rates of aging and neurodegeneration can be varied systematically. The development of murine genetic models of polyglutamine (polyQ) diseases with varying phenotypes and the existence of mouse lines with retarded aging offers the opportunity to develop models in which the interaction of aging and neurodegeneration can be studied systematically. We propose to develop compound mice lines carrying alleles that cause polyQ disease phenotypes and alleles that retard normal aging to study the impact of altering aging on the polyQ disease-like phenotypes. We focus on a phylogenetically conserved signaling pathway that influences aging in several invertebrate and vertebrate species;the Growth Hormone-insulin/IGF - Aki - FOXO pathway. Our hypothesis is that retarding aging by disrupting the Growth Hormone - insulin/IGF - Akt - FOXO pathway will delay mortality, and retard the development of behavioral and pathologic abnormalities secondary to induced polyQ mutations. This hypothesis is supported by impressive work in invertebrates but has not been tested in mammals.
Our specific aims are: 1) To generate compound mutant mice carrying a dominant HD-like transgene responsible for a moderately aggressive phenotype and 2 copies of a null mutation at the Pit1 (Snell dwarf) locus. 2) To generate compound mutant mice carrying a dominant HD-like transgene responsible for a moderately aggressive phenotype and 2 copies of a null mutation mutation at the Growth Hormone receptor (GHR) locus. 3) To characterize the lifespan, and behavioral and pathologic features of these compound mutants. Our long term goal is to understand the interaction of aging and neurodegeneration. If these experiments are successful, we will have models in hand to study the aging-neurodegeneration relationship. These models would be useful in dissecting the specific mechanisms underlying the aging-neurodegeneration relationship. We would be able to vary the rate of neurodegeneration by developing additional compound models with more slowly progressive polyQ disease alleles. We would be able to extend these approaches also to other neurodegenerations such as Alzheimer disease and Motor Neuron disease.

Public Health Relevance

The onset of most degenerative brain diseases, like Alzheimer disease and Parkinson disease, occurs later in life. Some unknown features of aging make the human brain susceptible to these degenerative disorders. We propose to develop new mouse models that will allow analysis of the interaction of normal aging and neurodegeneration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS059537-02
Application #
7681064
Study Section
Special Emphasis Panel (ZRG1-CDIN-T (03))
Program Officer
Sutherland, Margaret L
Project Start
2008-09-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2009
Total Cost
$133,263
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Neurology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Albin, Roger L; Miller, Richard A (2016) Mini-review: Retarding aging in murine genetic models of neurodegeneration. Neurobiol Dis 85:73-80
Kumar, Ashish; Zhang, Jennifer; Tallaksen-Greene, Sara et al. (2016) Allelic series of Huntington's disease knock-in mice reveals expression discorrelates. Hum Mol Genet 25:1619-36
Tallaksen-Greene, Sara J; Sadagurski, Marianna; Zeng, Li et al. (2014) Differential effects of delayed aging on phenotype and striatal pathology in a murine model of Huntington disease. J Neurosci 34:15658-68
Heng, Mary Y; Detloff, Peter J; Paulson, Henry L et al. (2010) Early alterations of autophagy in Huntington disease-like mice. Autophagy 6:1206-8
Tallaksen-Greene, Sara J; Janiszewska, Anita; Benton, Kasha et al. (2010) Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol 225:402-7
Heng, Mary Y; Duong, Duy K; Albin, Roger L et al. (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19:3702-20
Perry, Giselle M; Tallaksen-Greene, Sara; Kumar, Ashish et al. (2010) Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease. Hum Mol Genet 19:3354-71
Bohnen, N I; Müller, M L T M; Koeppe, R A et al. (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:1670-6